Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
2023-12-07 23:57:14 ET Summary MoonLake Therapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. Their lead product candidate, Sonelokimab, has shown best-in-class potential in treating Hidradenitis suppurativa and P...
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting PR Newswire Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability...
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting PR Newswire UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and d...
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States BIMZELX is the first and only IL-1...
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF) PR Newswire A post hoc analysis from the EXXELERATE Phase 4 trial showed that 65.7 percent of CIMZIA-treated patients with rheu...
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023 <ul type="disc"><li>Long-term data on investigational bimekizumab in the treatment of adults with ankylosing spondylitis showed sustained improvements for up...
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session UCB presents latest data from generalized mya...
NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on R...
2023-10-18 10:49:13 ET More on UCB SA Seeking Alpha’s Quant Rating on UCB SA Historical earnings data for UCB SA Dividend scorecard for UCB SA Financial information for UCB SA For further details see: FDA approves UCB's Bimzelx for plaque p...
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque p...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...